...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy
【24h】

The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy

机译:用紫杉烷基型佐剂化疗治疗的乳腺癌大队患者磷酸盐蛋白D1和P53途径与细胞周期蛋白D1和P53途径的预后价值

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The retinoblastoma (RB) gene is a tumor-suppressor gene that plays a central role in regulating the cell cycle. Inactivation of this gene is involved in breast cancer. Patients and Methods: A total of 827 patients with breast cancer treated with taxane-based adjuvant chemotherapy were included in the study. Protein expression of RB, phosphorylated RB (pRB), p16, cyclin D1 and p53 was evaluated by immunohistochemistry. Results: Neither of the retinoblastoma markers (RB and pRB) reached statistical significance in terms of their association with disease-free or overall survival. Nevertheless, when clustering analysis was performed, patients with tumors featuring low levels of p16, cyclin D1 and p53 with concomitantly high levels of pRB had reduced risk for relapse (Wald's p=0.015). Conclusion: The p53-mediated sensitivity of breast cancer cells to chemotherapeutic agents appears to be driven mostly by pRB. Using agents that enhance RB phosphorylation might possibly increase the chemosensitivity of breast cancer cells.
机译:背景:视网膜母细胞瘤(RB)基因是一种肿瘤抑制基因,在调节细胞周期中起着核心作用。该基因的失活参与乳腺癌。患者和方法:研究中共有827例乳腺癌治疗的乳腺癌患者,包括紫杉烷的佐剂化疗。通过免疫组织化学评估Rb,磷酸化Rb(PRB),P16,Cyclin D1和P53的蛋白质表达。结果:视网膜母细胞瘤标记(RB和PRB)都不达到与无疾病或整体存活的关联方面的统计学意义。然而,当进行聚类分析时,具有低水平P16,Cyclin D1和P53的肿瘤患者,具有伴随高水平的PRB的复发风险降低了(Wald的P = 0.015)。结论:P53介导的乳腺癌细胞对化学治疗剂的敏感性似乎主要由PRB驱动。使用增强Rb磷酸化的药剂可能会增加乳腺癌细胞的化学敏感性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号